BG
VERA icon

Bellevue Group’s Vera Therapeutics VERA Stock Holding History

Bellevue Group’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.4M Buy
1,710,808
+37
+0% +$1.38K 1.54% 24
2026
Q1 		$68.8M Buy
1,710,771
+12,619
+0.7% +$544K 1.64% 23
2025
Q4 		$86M Buy
+1,698,152
New +$60.3M 1.63% 20

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Bellevue Group's VERA Position: Q2 2026 in Review

Bellevue Group increased its Vera Therapeutics (VERA) stake by 0% in Q2 2026, buying an estimated $1.38K and bringing the position to 1,710,808 shares worth $73.4M. The position accounts for 1.54% of the portfolio, ranked #24.

Bellevue Group first reported a position in VERA in Q4 2025 and has held it in 3 quarters since. The position peaked at $86M in Q4 2025. 181 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Bellevue Group held 1,710,808 shares of Vera Therapeutics worth $73.4M as of Q2 2026.
  • Bellevue Group bought 37 Vera Therapeutics shares in Q2 2026, an estimated $1.38K.
  • Vera Therapeutics made up 1.54% of Bellevue Group's portfolio in Q2 2026, its #24 holding.
  • Bellevue Group first reported a position in Vera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Bellevue Group's Vera Therapeutics position peaked at $86M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.